New weekly injection shows promise for obesity – phase 2 trial complete
NCT ID NCT07177469
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new weekly injection called UBT251 in 205 overweight or obese adults to see if it helps with weight loss. Participants received different doses of the drug or a placebo for 24 weeks. The main goal was to measure the percentage change in body weight, with additional checks on waist size, BMI, and blood fats. The trial is now complete, and results will help decide if larger studies are needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UBT251 injection (a weekly shot for weight loss)
What this could lead to
If successful, this could lead to a new weekly injection option for managing obesity and related health issues like high blood pressure or fatty liver.
What could go wrong
This is an early Phase 2 study with only 205 people, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China